MedTrace Logo

Neurogenic Myocardial and Lung Injury in SAH Patients

NCT05408988 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-05-06

No results posted yet for this study

Summary

Up to this day, little is known whether the extent of brain damage in patients with SAH correlates with the degree neurogenic myocardial injury and neurogenic lung injury.

This is a prospective observational study designed to asses relationship between catecholamine surge and development of myocardial and lung injury in subarachnoid haemorrhage patients.

Conditions

  • Myocardial Injury
  • Lung Injury
  • Subarachnoid Hemorrhage

Interventions

DIAGNOSTIC_TEST

hs-TnT (high-sensitive cardiac troponin T) plasma concentration

hs-TnT plasma concentration measured once every 12 hours

DIAGNOSTIC_TEST

CK-MB (creatine kinase myocardial band) plasma concentration

CK-MB plasma concentration measured every 12 hours

DIAGNOSTIC_TEST

CPK (creatine phosphokinase) plasma concentration

CPK plasma concentration measured every 12 hours

DIAGNOSTIC_TEST

NT-proBNP (N-terminal prohormone of brain natriuretic peptide) plasma concentration

NT-proBNP plasma concentration measured every 12 hours

DIAGNOSTIC_TEST

Metanephrine concentration in urine

Metanephrine concentration measured in 12-hour urine collection using spectrophotometry.

Sponsors & Collaborators

  • Medical University of Silesia

    lead OTHER

Principal Investigators

  • Łukasz Krzych, PhD · University Clinical Center prof. K. Gibiński of the Medical University of Silesia in Katowice

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-22
Primary Completion
2024-06-30
Completion
2024-12-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05408988 on ClinicalTrials.gov